Immunizing against breast cancer: A new swing for an old sword

Breast

Volumn 18, Issue SUPPL.3, 2009, Pages

  Curigliano, Giuseppe ^a   Locatelli, Marzia ^a   Fumagalli, Luca ^a   Goldhirsch, Aron ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Breast cancer; Vaccines, breast cancer

Indexed keywords

APC 8024; BCG VACCINE; CANCER VACCINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2 VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HLA A2 ANTIGEN; MUCIN 1; THERATOPE; UNCLASSIFIED DRUG; VIRUS VACCINE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR IMMUNOLOGY;

EID: 71749104702     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(09)70273-5     Document Type: Article

References (31)

1. Schaefer N.G., Pestalozzi B.C., Knuth A., and Renner C. Potential use of humanized antibodies in the treatment of breast cancer. Expert Rev Anticancer Ther 6 7 (2006) 1065-1074
2. Acres B., Limacher J.M., and Bonnefoy J. Discovery and development of therapeutic cancer vaccines. Curr Opin Drug Discov Dev 10 2 (2007) 185-192
3. Nencioni A., Gruenback F., Patrone F., and Brossart P. Anticancer vaccination strategies. Ann Oncol 15 Suppl 4 (2004) 153-160
4. Lyerly H.K. Quantitating cellular immune response to cancer vaccines. Sem Oncol 30 3 Suppl 8 (2003) 9-16
5. Emens L.A., Reilly R.T., and Jaffee E.M. Augmenting the potency of breast cancer vaccines: combined modality immunotherapy. Breast Dis 20 (2004) 13-24
6. Ko B.K., Kawano K., Murray J.L., et al. Clinical studies of vaccines targeting breast cancer. Clin Cancer Res 9 9 (2003) 3222-3234
7. Curigliano G., Spitaleri G., Pietri E., et al. Breast cancer vaccines: a clinical reality or fairy tale?. Ann Oncol 17 5 (2006) 750-762
8. Melero I., Hervas-Stubbs S., Glennie M., Pardoll D.M., and Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 7 (2007) 95-106
9. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006) 126-129
10. Banchereau J., and Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5 (2005) 296-306
11. Adema G.J., de Vries I.J., Punt C.J., and Figdor C.G. Migration of dendritic cell based cancer vaccines: in vivo veritas?. Curr Opin Immunol 17 (2005) 170-174
12. Disis ML, Grabstein KH, Sleath PR, et al. HER2/neu peptide vaccines elicit T cell immunity to the HER2/neu protein in patients with breast or ovarian cancer. In: Proceedings of the 34th American Society Clinical Oncology, CA, USA, 16-19 May, 1998 (Abstract 97a).
13. Disis M.L., Schiffman K., Guthrie K., et al. Effect of dose on immune response in patients vaccinated with an HER2/neu intracellular domain protein-based vaccine. J Clin Oncol 22 10 (2004) 1916-1925
14. Knutson K.L., Schiffman K., and Disis M.L. Immunization with a HER2/neu helper peptide vaccine generates HER2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107 4 (2001) 477-484
15. Goydos J.S., Elder E., Whiteside T.L., et al. A Phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 63 1 (1996) 298-304
16. Marshall J., Hoyer R.J., Toomey M.A., et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 18 23 (2000) 3964-3974
17. Maclean G.D., Miles D.W., Rubens R.D., et al. Enhancing the effect of THERATOPE STnüKLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 19 4 (1996) 309-316
18. Mayordomo J, Tres A, Miles D, et al. Long-term follow-up of patients concomitantly treated with hormone therapy in a prospective controlled randomized multicenter clinical study comparing STnüKLH vaccine with KLH control in stage IV breast cancer following first-line chemotherapy. In: Proceedings of the 40th American Society Clinical Oncology, LA, USA, 5-8 June 2004 (22, Abstract 2603).
19. Melisko ME, Kenzer M, Jones L, et al. Vaccination with APC8024 (autologous dendritic cells loaded with antigen BA7072): immunologic and clinical activity in HER2/overexpressing breast cancer. In: Proceedings of the 39th American Society Clinical Oncology, IL, USA, 31 May-3 June, 2003 (22, 166 Abstract 665).
20. Kylstra JW, Park J, Jones L, Melisko M. Autologous antigen presenting cells loaded with BA7072 (APC8024) in patients with metastatic breast cancer overexpressing HER2/Neu: a Phase 1/2 study. In: Proceedings of the 39th American Society Clinical Oncology, IL, USA, 31 May-3 June, 2003 (22, 168 Abstract 673).
21. + breast cancer. In: Proceedings of the 41th American Society Clinical Oncology, FL, USA, 13-17 May, 2005 (Abstract 2520).
22. Gilewski T., Adluri S., Ragupathi G., et al. Vaccination of high risk breast cancer patients with MUC-1 keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 6 5 (2000) 1693-1701
23. Holmberg L.A., Oparin D.V., Gooley T., et al. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STnüKLH cancer vaccine. Bone Marrow Transplant 25 12 (2000) 1233-1241
24. Chui SY, Clay TM, Hobeika AC, et al. Dendritic cell vaccination following high dose chemotherapy with autologous stem cell support for breast cancer: long term follow up. In: Proceedings of the 39th American Society of Clinical Oncology, IL, USA, 31 May-3 June, 2003 (Abstract 682).
25. Wiseman C.L. Inflammatory breast cancer: ten-year follow-up of a trial of surgery, chemotherapy, and allogeneic tumor cell/BCG immunotherapy. Cancer Invest 13 3 (1995) 267-271
26. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 9 (2004) 909-915
27. Hoos A., Parmiani G., Hege K., Sznol M., Loibner H., Eggermont A., et al., Cancer Vaccine Clinical Trial Working Group. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 30 1 (1997 Jan) 1-15
28. Rovere P., Sabbadini M.G., Vallinoto C., Fascio U., Zimmermann V.S., Bondanza A., et al. Delayed clearance of apoptotic lymphoma cells allows cross-presentation of intracellular antigens by mature dendritic cells. J Leukoc Biol 66 (1999) 345-349
29. Turk J.L., and Parker D. Effect of cyclophosphamide on immunological control mechanisms. Immunol Rev 65 (1982) 99-113
30. Bass K.K., and Mastrangelo M.J. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother 47 (1998) 1-12
31. Berd D., Mastrangelo M.J., Engstrom P.F., Paul A., and Maguire H. Augmentation of the human immune response by cyclophosphamide. Cancer Res 42 (1982) 4862-4866